Peptide therapy in the US: the FDA reclassification explained

The FDA reclassified several peptides in 2025-2026, moving compounds between compounding categories, and the clinic market reorganized around what remained legal. The honest state:

What happened

The FDA's 503A/503B bulks-list process moved 14 peptides from restricted back to Category 1 (legal for compounding) - covered by AJMC as the "peptide reversal". Compounding pharmacies resumed supply; peptide menus reappeared at longevity and men's-health clinics nationwide.

What clinics actually sell now

The evidence honesty check

Human-trial evidence in healthy men is thin for nearly all compounds; marketing extrapolates animal and injury-model studies. GH secretagogues require IGF-1 monitoring because over-stimulation carries metabolic and cancer-risk questions. A clinic selling peptides without baseline labs and a monitoring schedule fails the same checklist logic as any other provider.

Pricing

$200-800 per month per compound is the clinic band reported in trade press, with men in their 40s cited as the demand driver. GLP-1s are their own economy. Nobody should stack peptides on TRT before TRT itself is stable and monitored.

Sources: AJMC; trade press; provider pages fetched 2026-10-08. Not medical advice.

Frequently asked questions

Are peptides like BPC-157 legal in the US?
Many popular peptides are not FDA-approved medicines and cannot legally be sold as drugs for human use; the FDA has warned about gray-market sellers. The safe, legal route is a licensed clinician prescribing within the law. We never list research-chemical vendors.
How much does peptide therapy cost at a clinic?
Published clinic pricing for peptide programs varies widely - commonly a few hundred dollars per month depending on the compound and protocol. Only enroll through a licensed provider who discusses risks and monitoring.
Affiliate disclosure: Some pages contain affiliate links, marked 'sponsored'. Featured placement is labelled on the page. Prices are published identically whether or not a provider has a commercial relationship with us.

Information directory — publicly available pricing compared, not medical advice · Source-checked 2026-10-09 · Independent directory — not medical advice.